Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)

Abstract

Integrin is a group of transmembrane glycoprotein that mediates cell-cell adhesion and signal transduction. It regulates cell adhesion, migration, proliferation, apoptosis and other functions. It is highly expressed on the surface of neovascular endothelial cells and a variety of malignant tumor cells. The peptides witharginine-glycine-aspartate (RGD) motif can specifically bind to multiplesubtypes of integrin including αVβ3. When labeled with radionuclides for single photon emission tomography (SPECT) or positron emission tomography (PET), the RGD-based peptides can non-invasively reveal the tumor characteristics, including invasion and metastasis, as well as evaluate angiogenesis in vivo. These methods have shown strong value in clinical application. Based on the home-and-abroad progress in relevant clinical research, this expert consensus aims to establish principles for clinical application of RGD-based peptides to integrin imaging.

Keywords

• integrin
• receptor imaging
• arginine-glycine-aspartate-based peptides
• expert consensus on clinical application